Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the OS, RFS, and TRM after HCT with low-dose total body irradiation, fludarabine, and busulfan conditioning.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Busulfan; Fludarabine; Fludarabine phosphate; Vidarabine

Criteria

Inclusion Criteria:

• At least 15 years old and not more than 65 years old.

• ECOG performance status 0-2.

• Patients with AML or MDS with intermediate/unfavorable cytogenetics.

• Patients with ALL and CML ineligible for Cy/TBI conditioning.

• Patients with NHL or HD eligible to myeloablative HCT.

• Patients receiving unrelated BMT for AML, MDS, ALL, CML, NHL or HD.

• Consent form signed and dated prior to study specific procedures.

• Subject able to comply with the scheduled follow-up and with the management of toxicities.

Exclusion Criteria:

-